# A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

> **NCT05784129** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 4 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Guselkumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05784129
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-21
- **Primary completion:** 2023-09-29
- **Final completion:** 2023-10-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Janssen made an internal business decision to discontinue the PROGRESS study. This decision is not related to any efficacy or safety concerns.
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05784129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05784129, "A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05784129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*